

Diagnostik nicht-muskelinvasiver Harnblasenkarzinome

Lennert Eismann, Yannic Volz, Boris Schlenker, Christian G. Stief, Jan-Friedrich Jokisch

Literatur

1. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136(5): E359–86
2. Richters A, Aben KKH, and Kiemeny LALM. The global burden of urinary bladder cancer: an update. *World J Urol* 2020; 38(8): 1895–904
3. Negri E and La Vecchia C. Epidemiology and prevention of bladder cancer. *Eur J Cancer Prev* 2001; 10(1): 7–14
4. DeGeorge KC, Holt HR, and Hodges SC. Bladder Cancer: Diagnosis and Treatment. *Am Fam Physician* 2017; 96(8): 507–14
5. Nadal R and Bellmunt J. Management of metastatic bladder cancer. *Cancer Treat Rev* 2019; 76: 10–21
6. Mainz A. DEGAM S1-Handlungsempfehlung: Nicht sichtbare Hämaturie (NSH). AWMF online, 2019. 2.1
7. Davis R et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. *J Urol* 2012; 188(6 Suppl): 2473–81
8. Satasivam P et al. The effect of oral anticoagulation on the prevalence and management of haematuria in a contemporary Australian patient cohort. *BJU Int* 2012; 110 Suppl 4: 80–4
9. Matulewicz RS et al. Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. *Bladder Cancer* 2017; 3: 45–49
10. Cavanaugh C and Perazella MA. Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019. *Am J Kidney Dis* 2019; 73(2): 258–72
11. (DKH), D.K.e.V.D.u.D.K., Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF), 2020. Langversion 2.20 (Konsultationsfassung)(AWMF-Registrierungsnummer 032/038OL)
12. Oliveira MCD et al. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. *Cancers* 2020; 12(6): 1400
13. Lin T et al. Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. *Oncol Lett* 2017; 13(5): 3928–34
14. Babjuk M et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) 2018, in European Association of Urology Guidelines. 2018 Edition. 2018, European Association of Urology Guidelines Office: Arnhem, The Netherlands
15. Zhu C-Z et al. A review on the accuracy of bladder cancer detection methods. *J Cancer* 2019; 10(17): 4038–44
16. Jokisch F et al. Prospective evaluation of 4-D contrast-enhanced-ultrasound (CEUS) imaging in bladder tumors. *Clin Hemorheol Microcirc* 2020; 74(1): 1–12
17. Rouprêt M et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma 2018, in European Association of Urology Guidelines. 2018 Edition. 2018, European Association of Urology Guidelines Office: Arnhem, The Netherlands

18. Galgano SJ et al. The Role of Imaging in Bladder Cancer Diagnosis and Staging. *Diagnostics* (Basel, Switzerland) 2020; 10(9): 703
19. Panebianco V et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). *Eur Urol* 2018; 74(3): 294–306
20. Vind-Kezunovic S et al. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. *Eur Urol Focus* 2019; 5(1): 90–6
21. Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006; 49(3): 466–5; discussion 475–7
22. Fernandez-Gomez J et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol* 2009; 182(5): 2195–203
23. Sylvester RJ et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. *Eur Urol* 2021; S0302-2838(20)31019-8